Skip to main content
Premium Trial:

Request an Annual Quote

Amaxa, Fisher's Dharmacon Pen siRNA Cell-Delivery Alliance

NEW YORK, June 6 (GenomeWeb News) - Fisher Biosciences' Dharmacon unit and German biotech Amaxa will "co-promote" data generated using Dharmacon's siRNA libraries with Amaxa's Nucleofector technology, the companies said today.
Dharmacon will work with Amaxa to provide combined customers with "technical service, pre-tested protocols, and application models to optimize the use of [Dharmacon's] siRNA reagents with the Amaxa technology," William Marshall, vice president of technology and business development for Fisher Biosciences, said in a statement.
Amaxa's Nucleofector 96-well Shuttle system is designed to allow parallel delivery of siRNA reagents into difficult-to-transfect cell lines.
Additional terms of the agreement were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.